Erratum for Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs

First published: 16 February 2020, https://doi.org/10.1111/jvim.15723

Volume 34, Issue 2.

Formatting errors in Table 3. Most common adverse events (AEs) and associated Veterinary Cooperative Oncology Group (VCOG) grades encountered in study population.

TABLE 3.

Most common adverse events (AEs) and associated Veterinary Cooperative Oncology Group (VCOG) grades encountered in study population. Multiple events are reported for each dog if encountered during the study

Grade	1	2	3	4	5
Gastrointestinal
Hyporexia	10	8	5 b
Diarrhea	14	11 c	3 c
Hematochezia/ melena	3	1
Vomiting	10	5	1 c
Weight loss	6	4	7 b , c
Hematologic
Anemia	11	1 c	1 a
Neutropenia	4	1	1	1 c
Thrombocytopenia	6	3 c	2 c	1 a
Cutaneous/Pulmonary
Dermatopathy	9 c	5	1 b
Pulmonary fibrosis	1
Pneumonia	1

^aEvan's syndrome suspected to be unrelated to rabacfosadine/L‐asparaginase.

^bAdverse events resulting in withdrawal from study in select cases.

^cAdverse events resulting in dose reduction or dose delay in select cases.

There are 3 groupings of events. The header of “Gastrointestinal” is only for “Hyporexia,” “Diarrhea,”

“Hemtaochezia/melena,” “Vomiting,” and “Weight loss.” There should be header of “Hematologic” for “Anemia,” “Neutopenia,” and “Thrombocyopenia” and a header of “Cutaneous/Pulmonary” for “Demotapathy,” “Pulmonary fibrosis,” and “Pneumonia.”

Correct display of Table 3 .